ArticleJournal of neurology2019
Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
Steffen Pfeuffer et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
11 papers cite it
this paperpooled ittrialcites it